Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06915974

Comparison Between Interleukin 6 and Procalcitonin in Detecting Sepsis and Incidence of Mortality in Burn ICU Patients

The investigators will compare the efficacy of Interleukin-6 (IL-6) as a better indicator than procalcitonin in burn patients with sepsis or septic shock regarding success of treatment and early ICU discharge.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Burns Death Infections Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms Sepsis Septic Shock Shock Shock, Septic Systemic Inflammatory Response Syndrome Wounds and Injuries

Age range

25 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10.

Treatment plan will be initiated to all patients according to the burn ICU protocol.

According to the lab results, interleukin 6 and procalcitonin will guide the investigators to take decisions regarding clinical improvement and ICU stay.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with acute burn admitted to burn ICU within 24 hours from the burn incidence.
  • patients with burn percentage of 25% to 50% of total body surface area
  • patients with second to third degree burns
  • ASA 1 and ASA 2 patients

Exclusion criteria

  • Burn percentage more than 50% or less than 25% of total body surface area
  • Having autoimmune diseases
  • Cancer patients
  • ASA 3 and ASA 4 patients

Treatment and study plan

interleukin 6

Diagnostic Test

Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10

Other names: Procalcitonin

Primary outcomes

  1. Occurrence of sepsis and septic shock

    Time frame: From day 1 to day 10 in burn ICU

    Prediction of occurrence of sepsis and septic shock

Secondary outcomes

  1. Length of ICU stay

    Time frame: One month after ICU admission

    Response to treatment and length of ICU stay for over one month

Study contacts

Contact information is provided by the study sponsor or research team.

Ahmed H Elsayed, M.B.B.CH

CONTACT

[email protected]

+201016305451

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Apr 8, 2025
Registry last updated
Apr 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.